Economics of non-adherence to biologic therapies in rheumatoid arthritis topical collection on health economics and quality of life

Current Rheumatology Reports

Volumn 16, Issue 11, 2014, Pages

  De Vera, Mary A ^a,b   Mailman, Jonathan ^a,c   Galo, Jessica S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

^c FRASER HEALTH AUTHORITY   (Canada)

Author keywords

Biologic agents; Costs; Health economics; Medication adherence; Patient compliance; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR;

ADVERSE OUTCOME; ARTICLE; BIOLOGICAL THERAPY; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SAFETY; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEALTH SERVICE; HUMAN; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; ECONOMICS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; HEALTH CARE COSTS; HUMANS; MEDICATION ADHERENCE;

EID: 84907232431     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-014-0460-5     Document Type: Article

References (55)

1. Dugowson CE, Koepsell TD, Voigt LF, Bley L, Nelson JL, Daling JR. Rheumatoid arthritis in women. Incidence rates in group health cooperative, Seattle, Washington, 1987-1989. Arthritis and. Rheumatism. 1991;34(12):1502-7.
2. Bykerk V, Emery P. Delay in receiving rheumatology care leads to long-term harm. Arthritis Rheum. 2010;62(12):3519-21.
3. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381-90.
4. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009;373(9664):659-72.
5. Lard LR, Visser H, Speyer I, van der Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001;111(6):446-51.
6. Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 2002;46(4):894-8.
7. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(1):27-35.
8. Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012;39(8):1559-82.
9. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625-39.
10. Consumer Reports and Consumer Reports Best Buy Drugs. Treating Rheumatoid Arthritis: Are Biologic Drugs Right for You? 2012.
11. Sabate E. Adherence to long-term therapies: Evidence for Action. Geneva: World Health Organization; 2003.
12. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.
13. Urquhart J, Vrijens B. New findings about ptaient adherence to prescribed drug dosing regimens: An introduction to pharmionics. Eur J Hosp Pharm Sci. 2005;11(5):103-6.
14. Treharne GJ, Lyons AC, Hale ED, Douglas KM, Kitas GD. 'Compliance' is futile but is 'concordance' between rheumatology patients and health professionals attainable? Rheumatology. 2006;45(1):1-5.
15. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-7.
16. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7-8):1280-8.
17. Mulherin D, Wong M. Drug survival in rheumatoid arthritis. Rheumatology. 2006;45(9):1178.
18. Koncz T, Pentek M, Brodszky V, Ersek K, Orlewska E, Gulacsi L. Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther. 2010;10(9):1367-78.
19. Treharne GLA, Hale ED, et al. Drug survival in rheumatoid arthritis - an interesting method but not a measure of adherence or corcodance. Rheumatology. 2006;45:1178-9.
20. Martinez-Santana V, Gonzalez-Sarmiento E, Calleja-Hernandez M, Sanchez-Sanchez T. Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis. Patient Prefer Adher. 2013;7:719-27. This is a recent observational studies of drug survival for anti-TNFs in RA published during the review period.
21. Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum. 2009;38(5):396-402.
22. de Achaval S, Suarez-Almazor ME. Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Rheumatol. 2010;5(3):313-26.
23. Pasma A, van't Spijker A, Hazes JM, Busschbach JJ, Luime JJ. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Semin Arthritis Rheum. 2013;43(1):18-28. A recent systematic review of non-adherence in rheumatoid arthritis, primarily on disease modifying anti-rheumatic drugs but also including biologics.
24. Salt E, Frazier SK. Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature. Orthop Nurs. 2010;29(4):260-75.
25. Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther. 2011;33(7):901-13.
26. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-35.
27. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum. 2008;59(10):1519-26. This study showed that having high out-of-pocket expenses is associated with lower medication adherence among RA patients on biologic therapy. (Outside of the review period but given limited studies on the topic of economics of non-adherence in RA, important to be annotated.).
28. Fernandez-Nebro A, Irigoyen MV, Urena I, Belmonte-Lopez MA, Coret V, Jimenez-Nunez FG, et al. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. J Rheumatol. 2007;34(12):2334-42.
29. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care. 2003;9(6 Suppl):S136-43.
30. Tang B, Rahman M, Waters HC, Callegari P. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther. 2008;30(7):1375-84. This is one of three studies that showed the relation between adherence to biologics and health care costs. Specifically, while adherent patients had higher total health care costs (driven by pharmacy costs), they had lower overall non-pharmacy costs. (Outside of the review period but given limited studies on the topic of economics of non-adherence in RA, important to be annotated.).
31. Borah BJ, Huang X, Zarotsky V, Globe D. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin. 2009;25(6):1365-77. This is one of three studies that showed the relationship between adherence to biologics (etanercept and adalimumab) and health care costs. Adherent patients had higher total health care costs but had fewer ambulatory, emergency room, and inpatient visits compared to non-adherent patients. (Outside of the review period but given limited studies on the topic of economics of non-adherence in RA, important to to annotated.).
32. Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel Jr EF, Griffin MR. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care. 2007;45(10 Supl 2):S66-76.
33. Li P, Blum MA, Von Feldt J, Hennessy S, Doshi JA. Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis. Value Health. 2010;13(6):805-12.
34. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303-10.
35. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther. 2006;8(6):R174.
36. Brocq O, Roux CH, Albert C, et al. TNF alpha antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone and. Spine. 2007;74(2):148-54.
37. Geborek PC M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002;61:793-8.
38. Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis. 2005;64(9):1274-9.
39. Stockl KM, Shin JS, Lew HC, Zakharyan A, Harada ASM, Solow BK, et al. Outcomes of a Rheumatoid Arthritis Disease Therapy Management Program Focusing on Medication Adherence. J Manag Care Pharm. 2010;16(8):593-604. This was an observational study of a disease therapy management intervention aimed at improving adherence to biologics in RA. Economic outcomes including costs and work productivity were evaluated. (Outside of the review period but given limited studies on the topic of economics of non-adherence in RA, important to be annotated.).
40. Agarwal SK, Maier AL, Chibnik LB, Coblyn JS, Fossel A, Lee R, et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum. 2005;53(6):872-8.
41. Markenson JGA, Palmer W, et al. Persistence with Anti-Tumor Necrosis Factor Therpaies in Patients with Rheumatoid Arthritis: Observations from the RADIUS registry. J Rheumatol. 2011;38(7):1273-81.
42. Briesacher BA, Gurwitz JH, Soumerai SB. Patients at-risk for cost-related medication nonadherence: a review of the literature. J Gen Intern Med. 2007;22(6):864-71.
43. Harrold LR, Briesacher BA, Peterson D, Beard A, Madden J, Zhang F, et al. Cost-related medication nonadherence in older patients with rheumatoid arthritis. J Rheumatol. 2013;40(2):137-43. This is the first study to demonstrate a high prevalence of cost-related non-adherence (CRNA) among RA patients receiving biologic therapies, as well as the impact of having RA experiencing CRNA and spending less on basic needs to afford medications.
44. Kawatkar AA, Jacobsen SJ, Levy GD, Medhekar SS, Venkatasubramaniam KV, Herrinton LJ. Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey. Arthritis Care Res. 2012;64(11):1649-56.
45. Wolfe F, Michaud K, Choi HK, Williams R. Household income and earnings losses among 6,396 persons with rheumatoid arthritis. J Rheumatol. 2005;32(10):1875-83.
46. Lenssinck ML, Burdorf A, Boonen A, Gignac MA, Hazes JM, Luime JJ. Consequences of inflammatory arthritis for workplace productivity loss and sick leave: a systematic review. Ann Rheum Dis. 2013;72(4):493-505.
47. Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA. Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med. 2005;118(5):515-20.
48. Wendling D, Materne GE, Michel F, Lohse A, Lehuede G, Toussirot E, et al. Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice. Joint Bone Spine: Rev Rhum. 2005;72(4):309-12.
49. Duclos M, Gossec L, Ruyssen-Witrand A, Salliot C, Luc M, Guignard S, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol. 2006;33(12):2433-8.
50. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 2009;61(5):560-8.
51. Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009;1173:837-46.
52. Yazici Y. Rheumatoid arthritis: When should we use rituximab to treat RA? Nat Rev Rheumatol. 2011;7(7):379-80.
53. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22-32.
54. Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Annals of the Rheumatic Diseases. Published online first November 27, 2013. This is one of the most recent observational studies of drug survival showing that after 5 years of follow-up, 38 % of infliximab, 55 % of etanercept, and 50 % of adalumimab initiators remained on their first therapy.
55. Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum. 2014;43(4):447-57. This is a recent observational study of drug survival for anti-TNFs in RA published during the review period.